LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s
… ProQR Announces Virtual Presentation at American Association … & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated … and Strabismus (AAPOS) held April 9-11, 2021. ProQR’s presentation Presentation title: A different type of …
… ProQR to Present Results from Phase 1/2 Trial of QR-421a for … & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … “Investors and Media” section of the Company’s website, www.ProQR.com . The dial-in details for the call are +1 …
… ProQR Announces Conference Presentations for Axiomer® RNA … the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … in May. Presentation at the TIDES 2018 Conference ProQR will deliver a presentation on the Axiomer ® RNA …
… ProQR Announces Presentations and Investor & Analyst Event at … LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …